Michael J. McGowan
Analyst · A.J. Rice with UBS
Thanks, Rand. The Oxford segment, consisting of the Oxford and CyberCoders business units, grew revenue by 1.3% on a pro forma basis to $125.9 million. Gross profit for the third quarter increased 6.4% over the third quarter of 2013 on a pro forma basis, and gross margin for the quarter was 43.1%. CyberCoders had a very strong quarter with record revenues approximately 25% greater than the third quarter of last year. We continue to be very pleased with CyberCoders' performance and the integration with the Oxford business unit as the synergy between the 2 has resulted in incremental perm placements. We also remain optimistic regarding continued growth as we continue to add staff recruiters to the CyberCoders team. Oxford's core revenue for the third quarter was $104.9 million, down sequentially by 1.2% and 2.3% over the third quarter of 2013. Oxford's core gross margin for the third quarter remained strong at 34.3%. The decline in revenue has been primarily due to the completion of several large health care IT projects and very sluggish demand for new electronic medical record projects and actual EMR assignments. Based on feedback from our clients, we expect new EMR implementations, optimizations of previously installed systems and overall demand for consultant use to slowly start to increase in 2015. We are also in the process of adjusting our service offerings in terms of EMR optimization and other required areas to address the ever-changing needs of the health care industry. Based on the projection of increased consultant use in 2015, we are making additional investments in our health care IT sales and delivery staffs. Oxford's other core division, Oxford International, has shown slight improvement throughout 2014, primarily driven by our regulatory and compliance and our traditional engineering segments. As reported on prior calls, our ERP and software, hardware engineering segments have been relatively soft throughout the year. Overall, though, Oxford International has been impacted by measured IT spending and some of our high-end specialized skills. Just as Apex is making investments in additional sales and delivery staff, we are doing the same in select segments and geographical areas that have realized growth in 2014 and projecting the same for 2015. VISTA, our physician staffing segment, experienced a good quarter as revenue was up 3.8% sequentially and 4.1% on a pro forma basis with the addition of Whitaker Medical acquired in December of last year. In addition, we have discussed previously, government demand has been inconsistent, but it is beginning to show signs of stability. Demand from our commercial clients is also starting to improve, and excluding our government business, we grew 13.1% year-over-year. From an industry perspective, the overall physician staffing market continues to experience choppy growth in the near term, but the macroeconomics that drives supply and demand in the segment remains positive. And finally, our Life Science segment in Europe had a respectable quarter, reflective of the softness of the overall European economy. Ed, now over to you.